Steen Elkjaer Husted

Steen Elkjaer Husted's AcademicInfluence.com Rankings

Philosophy

#9524

World Rank

#13099

Historical Rank

Logic

#6498

World Rank

#8020

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Steen Elkjaer Husted's Degrees

PhD Medicine Aarhus University
Doctorate Medicine Aarhus University

Why Is Steen Elkjaer Husted Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Steen Elkjaer Husted's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. (2009) (4964)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (2013) (3723)
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. (2003) (1350)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. (2016) (1176)
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study (1999) (1058)
Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) (872)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial (2010) (764)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. (2006) (744)
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study (2010) (628)
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. (2007) (624)
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial (2000) (623)
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. (2007) (519)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2011) (491)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial (2009) (486)
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis (2010) (478)
Darapladib for preventing ischemic events in stable coronary heart disease. (2014) (475)
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. (2007) (465)
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study (2010) (448)
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (2010) (443)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. (2009) (388)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. (2010) (356)
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. (1999) (339)
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (337)
Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist (2009) (318)
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial (2014) (312)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study (2006) (269)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial (2011) (268)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
Atropine resistance of transmurally stimulated isolated human bladder muscle. (1982) (259)
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). (2014) (252)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention (2013) (228)
Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation (2013) (205)
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. (2011) (186)
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (179)
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial (2014) (178)
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. (2013) (177)
Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial (2012) (176)
General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017) (166)
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). (2015) (162)
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel (2014) (161)
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. (2002) (157)
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. (2014) (148)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study (2013) (142)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* (2011) (136)
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (133)
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2012) (130)
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. (2016) (127)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial (2016) (125)
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. (2011) (116)
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease (2005) (112)
Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. (2015) (110)
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. (2012) (109)
High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2013) (109)
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis (2016) (109)
Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation (1994) (107)
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial (2014) (96)
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (96)
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. (2015) (94)
Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial (2012) (91)
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease (2016) (88)
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial (2014) (88)
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial (2015) (85)
Direct effects of adenosine and adenine nucleotides on isolated human urinary bladder and their influence on electrically induced contractions. (1983) (79)
Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study (2013) (72)
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). (2011) (68)
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 (2009) (68)
Doxazosin Treatment in Patients with Prostatic Obstruction (1993) (67)
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2015) (67)
Magnesium Inhibits Platelet Activity - an Infusion Study in Healthy Volunteers (1996) (67)
Guidelines on diagnosis and management of acute pulmonary embolism 1 (2000) (67)
Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. (2009) (66)
Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study (2016) (65)
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial (2014) (63)
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention (2016) (60)
Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel (2010) (58)
Acute valproate intoxication: biochemical investigations and hemodialysis treatment. (1983) (58)
Problems encountered in long-term treatment with anticoagulants. (2009) (57)
Contractile effects of some polypeptides on the isolated urinary bladder of guinea-pig, rabbit, and rat. (2009) (56)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. (2014) (54)
Urinary retention during i.m. and extradural morphine analgesia. (1982) (54)
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2012) (54)
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology (2015) (54)
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2015) (53)
Use of Antithrombotic Therapy and Long-Term Clinical Outcome Among Patients Surviving Intracerebral Hemorrhage (2016) (53)
Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. (1994) (53)
The pharmacokinetics of frusemide are influenced by age. (1983) (52)
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2014) (50)
CONTRIBUTION OF PROSTAGLANDINS TO THE ADENOSINE TRIPHOSPHATE‐INDUCED CONTRACTION OF RABBIT URINARY BLADDER (1980) (50)
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. (2017) (47)
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. (2012) (46)
New Oral Anticoagulants (2012) (44)
Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. (2015) (43)
Pharmacological and emerging therapies in the treatment of chronic angina (2015) (43)
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. (2015) (41)
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. (2015) (41)
Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation (2016) (40)
Treatment Changes among Users of Non‐Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation (2017) (39)
The influence of age on renal and extrarenal effects of frusemide. (1984) (38)
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (38)
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. (2015) (37)
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. (2002) (37)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. (1993) (35)
Early administration of intravenous magnesium inhibits arterial thrombus formation. (1997) (34)
The influence of age on the response to anticoagulants. (1977) (33)
A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy (2002) (33)
Dipyridamole and headache—a pilot study of initial dose titration (2004) (32)
The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids. (2002) (30)
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease (2012) (30)
Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo‐controlled trial (1989) (30)
Substance P and somatostatin and excitatory neurotransmission in rabbit urinary bladder. (1981) (30)
The determination of naproxen by spectrofluorometry and its binding to serum proteins. (2009) (30)
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes (2017) (30)
Mechanisms of the responses to non-cholinergic, non-adrenergic nerve stimulation and to ATP in isolated rabbit urinary bladder: evidence for ADP evoked prostaglandin release. (2009) (29)
Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey (2013) (29)
Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. (2005) (27)
Long-term anticoagulant therapy in patients with coronary artery disease. (2006) (27)
Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives (2015) (27)
178 fatal cases of pulmonary embolism in a medical department. (2009) (26)
New developments in oral antiplatelet therapy (2007) (26)
Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings. (1985) (26)
Magnesium inhibits human platelets. (1996) (25)
Intravenous Acetylsalicylic Acid – Dose-Related Effects on Platelet Function and Fibrinolysis in Healthy Males (1992) (25)
Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? (2003) (25)
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). (1997) (24)
Preadmission Oral Anticoagulant Treatment and Clinical Outcome Among Patients Hospitalized With Acute Stroke and Atrial Fibrillation: A Nationwide Study (2014) (24)
Role of prostaglandins in the responses of rabbit detrusor to non-cholinergic, non-adrenergic nerve stimulation and to ATP. (1980) (24)
Stress response and platelet function in minor surgery during epidural bupivacaine and general anaesthesia: effect of epidural morphine addition. (1989) (23)
Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. (1989) (23)
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. (2016) (23)
Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent (2004) (22)
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. (2013) (22)
Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. (1993) (22)
Renal effects of acute exposure to toluene. A controlled clinical trial. (2009) (21)
Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. (2017) (21)
Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. (2002) (20)
Inhibition of adrenergic neuroeffector transmission in rabbit pulmonary artery and aorta by adenosine and adenine nucleotides. (2009) (20)
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. (2014) (20)
A Review of the Literature with Particular Emphasis on Patients with Impaired Renal Function (2012) (19)
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial (2017) (19)
Effect of Postoperative Extradural Morphine on Lower Urinary Tract Function (1985) (18)
Platelet-Derived Growth Factor Release and Antiplatelet Treatment with Low-Dose Acetylsalicylic Acid (1993) (18)
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial (2009) (17)
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. (2016) (17)
Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. (2000) (17)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Renal effects of chronic exposure to organic solvents. A clinical controlled trial. (2009) (16)
The quality of routine oral anticoagulant therapy in a large geographical area. A survey of 310,300 inhabitants. (2002) (15)
Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration. (2018) (15)
Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial (2013) (15)
Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with atherothrombosis? (2009) (15)
Response to Letter Regarding Article, “Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO” (2012) (14)
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy (2017) (13)
TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CORONARY ARTERY BY-PASS SURGERY: RESULTS FROM THE PLATO TRIAL (2010) (13)
Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. (2016) (13)
Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban (2017) (12)
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. (2002) (12)
Thrombotic complications in coronary angioplasty — ionic versus non-ionic lowosmolar contrast media (1998) (12)
Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary Syndromes (2004) (12)
Deep vein thrombosis detection by 99mTc‐plasmin test and phlebography (1984) (12)
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrel (2014) (12)
Protein binding of phenprocoumon in the absence and presence of furosemide. (2009) (11)
Pharmacokinetics of sulfadiazine and trimethoprim in man (1978) (11)
Benefits and risks with antiplatelet therapy: how great a problem is bleeding? (2008) (11)
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents (2009) (11)
Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes (2015) (10)
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y 12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes (2007) (10)
APIXABAN REDUCES HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS OF THE EFFECT OF APIXABAN THERAPY ON RESOURCE USE IN THE APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION TRIAL (2013) (10)
Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation (2013) (10)
Effect of postoperative extradural morphine on lower urinary tract function. (1985) (10)
Preadmission oral anticoagulant therapy and clinical outcome in patients hospitalised with acute stroke and atrial fibrillation. (2014) (10)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO AGE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2013) (10)
Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. (2009) (9)
Percutaneous Transluminal Coronary Angioplasty versus Thrombolysis in Acute Myocardial Infarction: A Prospective, Matched, Controlled Study (2000) (9)
TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS (2014) (9)
Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction). (1994) (9)
Evaluating the Risk-Benefit Profile of the Direct-Acting P2Y12 Inhibitor Ticagrelor in Acute Coronary Syndromes (2011) (8)
Haemostatic Activity in Patients with Atrial Fibrillation Treated with Low-Molecular-Weight Heparin Before and After Electrical Cardioversion (2004) (8)
[Deep venous thrombosis--who, what, why?]. (2007) (8)
Dual inhibitory action of ATP on adrenergic neuroeffector transmission in rabbit pulmonary artery. (1985) (8)
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. (2012) (8)
Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment (1989) (8)
A new automated technique for platelet aggregation measurement. (1984) (8)
Oral antiplatelet agents in ACS: from pharmacology to clinical differences (2011) (8)
Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction. (2000) (8)
Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO (2010) (8)
Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark (2017) (7)
The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon. (2009) (7)
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (7)
Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients (2015) (7)
[Deep venous thrombosis--epidemiology, diagnosis and treatment]. (2007) (7)
TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL (2013) (7)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN (2012) (7)
Renal blood flow and pelvic pressure after 4 weeks of total upper urinary tract obstruction in the pig (1988) (7)
Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. (2001) (7)
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes (2016) (7)
The binding of aprindine to serum proteins with statistical considerations concerning the analysis of binding data. (2009) (7)
Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study (2009) (7)
A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. (2007) (7)
TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY (2010) (6)
Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel” (2014) (6)
A critical review of clinical trials for low‐molecular‐weight heparin therapy in unstable coronary artery disease (2001) (6)
Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial. (1989) (5)
Dyspnoea and antiplatelet agents: revisited (2007) (5)
Individual variation in the response to phenprocoumon (2004) (5)
[Liver and kidney function in stainless steel welders]. (1981) (5)
Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment (2015) (5)
Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion (2019) (4)
[Antithrombotic treatment in cardiovascular diseases. A report by a working group of the Danish Cardiologic Society and the Danish Society of Clinical Chemistry]. (1997) (4)
[Prevention of postoperative venous thrombosis. A comparison between low-dose heparin and graduated compression stockings]. (1985) (4)
Observer variation in the interpretation of ventilation-perfusion lung scintigraphy (1994) (4)
Coronary Heart Disease Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention (2010) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
[Interaction between thrombocytes and blood vessel wall--significance for acute ischemic coronary syndromes]. (1995) (4)
[Superficial thrombophlebitis. Etiology, diagnosis and treatment]. (2008) (4)
THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL (2010) (4)
Heparin-induced increase in serum levels of aminotranferases. A controlled clinical trial. (1984) (4)
Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism. (2004) (4)
Prazosin treatment of neurological patients with lower urinary tract dysfunction (1993) (4)
Heparin-Induced Increase in Serum Levels of Aminotransferases (2009) (4)
Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability (2004) (4)
The effect of daily administration of naproxen on the prothrombin complex activity in patients under long-term therapy with phenprocoumon. (1979) (3)
Recent advances in the diagnosis and treatment of deep vein thrombosis: a regional consensus. (2003) (3)
The binding of phenprocoumon to human plasma proteins. (2009) (3)
[Percutaneous transluminal coronary angioplasty in acute myocardial infarction. A prospective controlled study]. (1998) (3)
Bedside Coagulometry During Intravenous Heparin Therapy after Coronary Angioplasty (2001) (3)
Intravenous acetylsalicylic acid, magnesium and their combination in experimental arterial thrombosis in rats. (1999) (3)
Increased sensitivity to phenprocoumon during methyltestosterone therapy (1976) (3)
Topographic variations in alpha-adrenergic and cholinergic response in the pig renal pelvis. (1983) (3)
ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL (2014) (3)
REDUCTION IN PULMONARY ADVERSE EVENTS AND ASSOCIATED SEPSIS AND MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH TICAGRELOR COMPARED TO CLOPIDOGREL: A POST HOC ANALYSIS OF THE PLATO STUDY (2012) (3)
Abstract 5494: Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease (2009) (3)
TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (3)
Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial (2011) (3)
[Venous thromboembolism. "The emperor's new clothes" or a silent menace?]. (1990) (3)
Coronary angiography in relation to troponin T level in patients with unstable coronary artery disease (UCAD) - a FRISC-2 substudy (2000) (3)
Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment : a substudy from the prospective randomized PLATelet inhibit (2013) (2)
Abstract 18856: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
Abstract 19384: Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
POORLY CONTROLLED BLOOD PRESSURE IS INDEPENDENTLY ASSOCIATED WITH A 50% HIGHER RISK OF STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2014) (2)
Balancing the risk of ischaemic and bleeding events in ACS (2015) (2)
[Pulmonary embolus after adder bite]. (2014) (2)
The influence of intravenous furosemide on the renal excretion pattern of protein and protein degradation products. (2009) (2)
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". (2014) (2)
Planned invasive compared to conservative treatment in patients with negative high sensitivity troponin at randomization in patients with non-st-elevation acute coronary syndrome - a platelet inhibition and patient outcomes (plato) trial blood-core subgroup analysis (2012) (2)
2799 – EFFECT OF ADENOSINE AND ADENINE NUCLEOTIDES ON VASCULAR NEUROEFFECTOR TRANSMISSION (1978) (2)
[The value of anticoagulant therapy in deep venous thrombosis]. (1981) (2)
Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLA (2012) (2)
[Tennis leg--a differential diagnosis in deep vein thrombosis]. (1989) (2)
Principles of thromboprophylaxis in surgical patients. (1991) (2)
THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS (2013) (2)
Pelvic pressure measurements in the totally obstructed pyeloureter of the pig in 4 weeks. (1988) (2)
[Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor]. (2001) (2)
Dipyridamole and Platelet Release of Platelet-derived Growth Factor. (1994) (2)
Dyspnoea after AZD6140: safety first?: reply (2006) (2)
Inadequate use of prophylaxis against venous thromboembolism in Danish medical departments. (2011) (2)
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. (2000) (2)
Abstract 16741: The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group (2014) (2)
Better outcome after 2 years with an early invasive strategy in unstable coronary artery disease (UCAD) - FRISCII 2 year follow-up. (2001) (2)
[Severe poisoning with thyroid hormones in a body builder]. (1983) (2)
Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease (2006) (2)
Antiplatelet therapy in acute coronary syndromes: ticagrelor. (2012) (2)
Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment (1989) (1)
USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (1)
[Acetylsalicylic acid in plasma after oral administration]. (1982) (1)
Plasma thromboxane B2 as an early marker of acute graft rejection after heart transplantation: preliminary report. (1991) (1)
Effect of bepridil on metabolic control and insulin secretion in diabetics (2004) (1)
The protective effects of long-term lmw heparin (dalteparin) treatment in unstable CAD is confined to patients not previously treated with statins (2000) (1)
[Fatal pulmonary embolism in a medical department. Clinic-pathological correlations and therapeutic deliberations]. (1981) (1)
CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS) (2011) (1)
[The use of venous thromboprophylaxis in Danish medical departments. A questionnaire survey]. (2005) (1)
ANTICOAGULANT THERAPY AND PULMONARY EMBOLISM (1982) (1)
Inhibition and Patient Outcomes (PLATO) Trial In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet ST-Elevation Acute Coronary Syndrome Patients Managed With or Without − Non Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in (2014) (1)
RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2012) (1)
[Heparin-induced increase in serum aminotransferase]. (1984) (1)
Effect of Low-Molecular-Weight Heparin (Tinzaparin) and Unfractionated Heparin on Platelet Aggregation (1996) (1)
Activated Leukocyte Cell Adhesion Molecule (ALCAM) And Outcomes In Acute Coronary Syndromes : A Plato Biomarker Substudy (2015) (1)
Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel (2012) (1)
CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS (2012) (1)
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment (2014) (1)
[The antithrombotic-treated patient]. (2006) (1)
REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY (2012) (1)
GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study (2013) (1)
Abstract 4947: Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy (2009) (1)
[Clinical studies on glycoprotein IIb/IIIa receptor antagonist]. (2000) (1)
Treatment of pulmonary embolism at home? (2010) (1)
Abstract 15029: Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial (2011) (1)
Cardiac Arrest Caused by Multiple Recurrent Pulmonary Embolism (2011) (1)
Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
Abstract 14643: Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial (2014) (1)
Abstract 13713: Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study (2013) (1)
Oral Direct Thrombin Inhibitors and Oral Factor Xa Inhibitors (2012) (0)
[Terodiline (Mictrol)]. (1987) (0)
[Antithrombotic therapy in ischemic stroke and transient ischemic attack]. (2007) (0)
Peroral AK-behandling (2010) (0)
Abstract 15603: Does Repeat Measurement of High Sensitivity Troponin I Improve Prediction of Cardiovascular Events in Atrial Fibrillation? (2014) (0)
[Fibrinolytic agents in acute myocardial infarction. Reperfusion--a two-edged sword? Advantages and disadvantages of various preparations]. (1989) (0)
PLATELET FUNCTION AND ENDOCRINE STRESS RESPONSE DURING EPIDURAL AND GENERAL ANAESTHESIA FOR MINOR SURGERY OF THE LOWER LIMBS (1987) (0)
[Is Danish percutaneous coronary intervention too centralized?]. (2012) (0)
Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy (2013) (0)
The n e w e n g l a n d j o u r n a l of m e d i c i n e Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease (2017) (0)
Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply (2007) (0)
Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex : Results From the ARISTOTLE Trial (2013) (0)
Effect of time to interventional treatment on NSTE-ACS outcomes in PLATO (2015) (0)
USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2017) (0)
Low molecular weight heparin (dalteparin) as a "bridge-to-revascularisation" - one year follow-up of patients appropriate for early revascularisation in the noninvasive cohort of the FRISC2 trial (2000) (0)
[Flying High]. (2013) (0)
[Acetylsalicylic acid in acute ischemic coronary and cerebral diseases]. (1989) (0)
[Acetylsalicylic acid and renal damage. Evaluation of the role of acetylsalicylic acid in the development of analgesic nephropathy]. (1983) (0)
[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. (1989) (0)
[Apical hypertrophic cardiomyopathy]. (1991) (0)
Use of oral anticoagulation therapy and long-term clinical outcome among atrial fibrillation patients surviving intracerebral hemorrhage (2015) (0)
[Can deep venous thrombosis be excluded by D-dimer test?]. (2008) (0)
Abstract 16755: Association Between Achievement of Risk Factor Standard of Care Goals and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease in the STABILITY Trial (2015) (0)
Stroke Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (0)
Direct oral P2Y12 inhibition: AZD6140 (Ticagrelor) (2008) (0)
Development of a novel biomarker-based clinical prediction model for major adverse cardiovascular events in revascularized patients with acute coronary syndromes (2015) (0)
[Danish Society for Thrombosis and Hemostasis]. (1994) (0)
Recent advances in the diagnosis and treatment of deep vein thrombosis (2003) (0)
SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2016) (0)
[Clopidogrel: background information and use in clinical practice]. (2003) (0)
[Control of anticoagulant treatment]. (1992) (0)
[Pulmonary embolism. A diagnostic and therapeutic dilemma]. (1983) (0)
[Thrombolytic therapy in apoplexy]. (1999) (0)
Clinical Investigations Changes in Inﬂammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel (2010) (0)
Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy (2015) (0)
[Criteria for Plavix (clopidogrel) administration]. (2003) (0)
[Optimal acute treatment of high-risk pulmonary embolism]. (2013) (0)
RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2014) (0)
Ny og gammel antikoagulerende behandling (2013) (0)
[Employment of calcium antagonists in extracardial diseases]. (1986) (0)
[Lethal recurrent pulmonary embolism]. (2012) (0)
Dyspnoea after AZD6140 : safety first? Author's reply (2006) (0)
Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2015) (0)
[Antihypertensive treatment after apoplexy--protective effects against cardiovascular disease in addition to reduction of blood pressure?]. (2006) (0)
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. (2010) (0)
Lungeemboli efter hugormebid (2014) (0)
Comparison of outcomes in patients randomized to warfairn according to anticoagulant control: results from Sportif III (2007) (0)
The Indication for Antithrombotic Primary Prophylaxis and Treatment in Case of Thromboembolic Complications in Patients with Metabolic Syndrome (2013) (0)
Invasive strategy improves survival for people with unstable coronary disease, but also increases costs (2002) (0)
Substantial differences in initiation of antithrombotic treatment and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings: a nationwide cohort (2013) (0)
Primary percutaneous coronary intervention delay for patients living in a peripheral area in Denmark. (2013) (0)
[Acetylsalicylic acid in the treatment of arterial thromboembolic diseases. 1. Pharmacologic aspects]. (1989) (0)
Cardioversion-related stroke (2016) (0)
Abstract 13938: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Biomarkers Associated With Increased Cardiovascular Risk in Patients With Stable Coronary Heart Disease in the Global STABILITY Trial (2015) (0)
Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study (2013) (0)
CHARACTERIZATION OF THE MYOCARDIAL INFARCTION ENDPOINTS, IMPACT OF EVENT ADJUDICATION, AND TICAGRELOR EFFECTS IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2013) (0)
Acute effects of acetylsalicylic acid on renal and hepatic function in normal humans. (1985) (0)
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. (2010) (0)
PLATELET FUNCTION AND ENDOCRINE STRESS RESPONSE DURING BUPIVACAINE EPIDURAL ANALGESIA. THE EFFECT OF MORPHINE ADDITION (1987) (0)
Abstract 16157: Single Measurement of GDF-15 Provides Reliable Prognostication of Stroke and Major Bleeding in Atrial Fibrillation (2014) (0)
[Peroral antithrombotic treatment]. (2006) (0)
Endoskopi af patienter i antikoagulerende behandling I (2009) (0)
Lower risk of myocardial infarction in atrial fibrillation patients treated with vitamin K antagonist than in combination with acetylsalicylic acid (ASA) or ASA alone (2015) (0)
[New and old anticoagulant therapy]. (2013) (0)
[Perioperative heparin bridging is rarely indicated]. (2016) (0)
[Prevention of apoplexy]. (1999) (0)
[The present status regarding the preventive treatment of deep venous thromboembolism]. (1985) (0)
Lower Mortality RAtes with TNK-tPA in Late-Treated Patients: REsults from the ASSENT-2 Study (2001) (0)
[Anticoagulant therapy in 2012--individualized treatment--also for the elderly]. (2012) (0)
[Acetylsalicylic acid therapy and vascular surgery]. (1994) (0)
[The value of 99mTc-plasmin scanning in deep venous thrombosis]. (1984) (0)
[Abciximab (ReoPro) in the treatment of acute coronary syndromes]. (2001) (0)
[Acetylsalicylic acid and cerebral hemorrhage]. (1992) (0)
The imbalance of coagulation and fibrinolysis in coronary heart disease and its relation to traditional risk factors (1996) (0)
[Anticoagulant treatment]. (2000) (0)
[Anticoagulant therapy in stroke patients]. (2013) (0)
PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL (2016) (0)
[Anticoagulant and thrombolytic therapy in deep venous thrombosis and pulmonary embolism]. (1995) (0)
[Endoscopy in patients receiving anticoagulation therapy I]. (2009) (0)
[Diagnosis and treatment of pulmonary embolism in Denmark. A questionnaire study]. (1984) (0)
[Monitoring options and reversal agents for oral anticoagulants]. (2014) (0)
[Treatment with adrenergic alpha receptor blockaders in benign prostatic hypertrophy]. (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Steen Elkjaer Husted?

Steen Elkjaer Husted is affiliated with the following schools: